Brian A Sherer

USPTO Granted Patents = 23 (Patent Applications = 12)

CIPO Patents = 1 (Patent Applications = 8)

EPO Patents = 8 (Patent Applications = 12)

Average Co-Inventor Count = 2.7

ph-index = 3

Forward Citations = 60(Granted Patents)

Location History:

Waltham, MA (US) (2010 - 2013)
Nashua, NH (US) (2013 - 2023)

Company Filing History:

Years Active: 2010-2023

Loading Chart...

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11629134 - TLR7/8 antagonists and uses thereof (2023-04-18),

2. 11512069 - TLR7/8 antagonists and uses thereof (2022-11-29),

3. 11440899 - Pyrimidine TBK/IKKe inhibitor compounds and uses thereof (2022-09-13),

4. 11098041 - Heteroaryl compounds as BTK inhibitors and uses thereof (2021-08-24),

5. 10947214 - TLR7/8 antagonists and uses thereof (2021-03-16),

6. 10947213 - TLR7/8 antagonists and uses thereof (2021-03-16),

7. 10836750 - TLR7/8 antagonists and uses thereof (2020-11-17),

8. 10793553 - TLR7/8 antagonists and uses thereof (2020-10-06),

9. 10696649 - TLR7/8 antagonists and uses thereof (2020-06-30),

10. 10544122 - TLR7/8 antagonists and uses thereof (2020-01-28),

11. 10428080 - TBK/IKK inhibitor compounds and uses thereof (2019-10-01),

12. 10399957 - TLR7/8 antagonists and uses thereof (2019-09-03),

13. 10377745 - Heterocyclic compounds as NaV channel inhibitors and uses thereof (2019-08-13),

14. 10329297 - Compounds for the inhibition of indoleamine-2,3-dioxygenase (2019-06-25),

15. 10253023 - Heteroaryl compounds as BTK inhibitors and uses thereof (2019-04-09),

Title: Brian A. Sherer: Innovator in TLR7/8 Antagonist Research

Introduction: Brian A. Sherer is a prominent inventor based in Nashua, New Hampshire, known for his significant contributions to the field of pharmaceutical research. With a portfolio of 23 patents, Brian has made remarkable advancements in the development of TLR7/8 antagonists, which hold potential therapeutic benefits for various disorders.

Latest Patents: Among his recent patents, Sherer has developed compounds and methods that focus on TLR7/8 antagonists. His work includes the formulation of compounds of Formula 1 and the creation of pharmaceutically acceptable compositions designed to inhibit TLR7/8 activity. Additionally, he has patented methods for administering these compounds to patients in need, which can help treat TLR7/8-mediated disorders.

Career Highlights: Throughout his career, Brian has been affiliated with notable pharmaceutical companies, including Merck Patent GmbH and AstraZeneca. His work in these organizations has contributed to vital research and innovation in the pharmaceutical industry, particularly in immunology and drug development.

Collaborations: Brian has collaborated with various professionals in the field, including notable colleagues like Nadia Brugger and Xiaoling Chen. These collaborations have fostered a productive research environment, leading to impactful advancements in the applications of TLR7/8 antagonists.

Conclusion: Brian A. Sherer's innovative work has positioned him as a leading inventor in the pharmaceutical sector. His development of TLR7/8 antagonists and methods for their use underscores his commitment to improving healthcare outcomes through research and innovation. As he continues to advance his work, the impact of his inventions may contribute significantly to the treatment of complex medical conditions.

This text is generated by artificial intelligence and may not be accurate.